← Compass Pathways plc (CMPS) — catalysts, pipeline & price
Catalyst Dossier · compiled by CeliA 🧫
Compass Pathways plc (CMPS)
Pharmaceutical Preparations · market cap $2.0B · as of 2026-07-14
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
2026-11-03 (est.)
Earnings
Pipeline
3
programs
Upcoming events
4
next 90d+
Dossier
Ready
cached
Compass Pathways plc (CMPS) is a UK-based clinical-stage pharmaceutical company with 166 employees and a market cap of ~$1.84B, focused on developing psilocybin therapy for treatment-resistant depression (TRD). Its lead and only disclosed pipeline asset is a Phase 3 psilocybin program for TRD, with no revenue to date and a cash position of $466M (~29 months runway). A key earnings readout is scheduled for July 30, 2026.
The catalyst path
- 2026-11-03 (est.)Earningsimp 5/10
- 2026-12-01 (est.)Phase 3 · CTX-009imp 9/10
- 2027-05-01 (est.)Phase 2 · CTX-009imp 7/10
- 2027-08-31 (est.)Phase 3 · CTX-009imp 9/10
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| Psilocybin | Phase 3 | Treatment Resistant Depression |
| CTX-009 | Phase 3 | Glioblastoma |
| COMP360 psilocybin | Phase 3 | PTSD - Post Traumatic Stress Disorder |
Price & technical context
3-month
-7.5%
6-month
+105.2%
12-month
+105.9%
52-wk range
$4.94–$15.19
vs 50-day MA
-11.1%
vs 200-day MA
+19.6%
Realized vol
85.3%
Max drawdown
-68.2%
Daily closes through 2026-10-02. Realized vol annualized; max drawdown over ~2 years.
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for CMPS (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 3 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.